Zonisamide for migraine prophylaxis in topiramate-intolerant patients: An observational study

Headache

Volumn 51, Issue 2, 2011, Pages 287-291

  Villani, Veronica ^a   Ciuffoli, Alessandro ^a   Prosperini, Luca ^b   Sette, Giuliano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

disability; migraine; topiramate; zonisamide

Indexed keywords

TOPIRAMATE; ZONISAMIDE;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MENTAL CONCENTRATION; MIGRAINE; MOOD DISORDER; OBSERVATIONAL STUDY; PARESTHESIA; PHARMACODYNAMICS; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WEIGHT REDUCTION;

EID: 79551595341     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01842.x     Document Type: Article

References (16)

1. Frediani F,. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci. 2004; 25: S161-S166.
2. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004; 61: 490-495. (Pubitemid 38923736)
3. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA. 2004; 291: 965-973.
4. Diener HC, Tfelt-Hansen P, Dahlo C, et al. Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004; 251: 943-950.
5. Akerman S, Goadsby PJ,. Topiramate inhibits trigeminovascular activation: An intravital microscopic study. Br J Pharmacol. 2005; 146: 7-14.
6. Angehagen M, Ben-Menachem E, Ronnback L, et al. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res. 2003; 28: 333-340.
7. Frampton JE, Scott LJ,. Zonisamide: A review of its use in the management of partial seizures in epilepsy. CNS Drugs. 2005; 19: 347-367.
8. Biton V,. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol. 2007; 30: 230-240.
9. Kito M, Maehara M, Watanabe K,. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure. 1996; 5: 115-119.
10. Leppik IE,. Zonisamide: Chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004; 13: 5-9.
11. Drake ME, Greathouse NI, Renner JB, Armentbright AD,. Open-label zonisamide for refractory migraine. Clin Neuropharmacol. 2004; 27: 278-280.
12. Bermejo PE, Dorado R,. Zonisamide for migraine prophylaxis in patients refractory to Topiramate. Clin Neuropharmacol. 2009; 32: 103-106.
13. Headache Classification Committee. The international classification of headache disorders. 2nd Edition. Cephalalgia. 2004; 24: 1-160.
14. D'Amico D, Mosconi P, Genco S, et al. The Migraine Disability Assessment (MIDAS) questionnaire: Translation and reliability of the Italian version. Cephalalgia. 2001; 21: 947-955.
15. Ashkenazi A, Benlifer A, Korenblit J, Silberstein SD,. Zonisamide for migraine prophylaxis in refractory patients. Cephalalgia. 2006; 26: 1199-1202.
16. Pakalnis A, Kring D,. Zonisamide prophylaxis in refractory pediatric headache. Headache. 2006; 46: 804-807.